Osborne Clarke has advised PL BioScience GmbH in a EUR 7.8 million Series A financing. The Aachen-based biotechnology company conducts research in the field of sustainable, animal-free cell culture media. PL BioScience's innovative Human Platelet Lysate (HPL) technology is expected to enable groundbreaking developments in cell therapy. 

The growth financing round attracted significant investments from AVANT BIO (New York), LePure Biotech (Shanghai), b.value AG (Dortmund) and better ventures (Munich). The consortium joins a group of existing investors led by Brightlands Venture Partners (Geleen) and TechVision Fonds (Aachen), who have again pledged their support.

Pioneering cell culture technology from Aachen

HPL is obtained from donated blood that is no longer suitable for transfusions and offers a sustainable and effective alternative to cell culture media of animal origin. HPL enables a more seamless transferability of research results to humans. The technology ensures reliable results in laboratories worldwide, paving the way for advances in regenerative medicine.

Massive growth forecast for cell culture media

The company's extensive customer base, which includes leading companies from the life science and biomedical sectors as well as research institutions and university hospitals, relies on PL BioScience's HPL for the development of cellular therapies. The global market for stem cell therapy is forecast to grow from USD 15 billion in 2024 to USD 63 billion in 2031, more than quadrupling in terms of market volume. (Source: Global Stem Cell Therapy Market, Coherent Market Insights, 2024). 

Christian Wilkes, co-founder and CFO of PL BioScience, emphasises the strategic importance of international partnerships: „By offering high-quality, animal-free growth media, we have been able to establish a solid reputation both locally and globally. The participation of investment companies from Europe, the USA and China accelerates our global growth strategy and strengthens our presence in these emerging geographic markets.“

The Osborne Clarke team was led by Dr Benjamin Monheim (Corporate / VC) and comprised Fenja Striesow and Benedikt Hülsmann (both Corporate / VC), Carsten Dau and Sarah Grigo (both Commercial), Dr Andrea Schmoll and Dr Jonas Völkel (both IP) as well as Patrick Seiler and Florian Merkle (both Tax).

Share
Corporate communications and press contacts
If you are a journalist and would like comment or background from our legal experts, we can help. Our team will put you in touch with the best person. View a full list of our international press contacts by jurisdiction here.

Connect with one of our experts